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Abstract
Background: The management of cutaneous metastases often represents a challenge because they may be
widespread and may recur after radiotherapy or chemotherapy; breast cancer accounts for 51% of the total cases
of cutaneous metastases. When surgical excision of chest wall recurrences is not possible and other local
treatments such as radiotherapy or radiotherapy with hyperthermia fail, topical chemotherapy and
electrochemotherapy (ECT) might be taken into account.
ECT is a new local treatment of solid tumors which can be defined as the local potentiation, by means of
permeabilizing electric pulses, of the antitumor activity of a non permeating anticancer drug with high intrinsic
cytotoxicity.
Methods: This prospective observational study took place throughout March 2010 to October 2011. Twelve
consecutive elderly patients (1 man and 11 women, median age of 76 years) with regional or distant skin or
subcutaneous metastases from breast cancer, with or without visceral disease, were included in the study. Patient
enrollment was carried out according to the ESOPE criteria. Bleomycin administration was followed by the
application of brief electric pulses to each tumor nodule within 8 min after intravenous infusion of the drug.
Electric currents were delivered by means of a 2–3 cm long needle electrode according to lesion size. All
treatments were performed using the CliniporatorTM device.
Results: We observed Complete Response(CR) in 75.3% (107 metastases), Partial Response(PR) in 17% (24
metastases), no change in 7.7% (11 metastases) . No serious ECT-related adverse events were reported; adverse
events consisted of pain in the treated area one to two days after treatment (1 patient, 8.3%) and ulceration of
treated area (1 patient, 8.3%).
Conclusion: ECT could be suggested as a primary local therapy in patients not suitable for surgical removal of the
primary tumor, and clinicians should not hesitate to use it even in the elderly.
Background
Skin metastases from breast cancer are relatively com-
mon and sometimes impair quality of life. Review of the
literature indicates that the incidence of cutaneous
metastases for all types of carcinomas ranges from 0.7%
to 10.0% [1][2]. Breast cancer accounts for 51% of the
total cases of cutaneous metastases [1,2].
The management of cutaneous metastases often repre-
sents a challenge for the clinician, and surgical excision
might be followed by radiotherapy and systemic treatment.
When surgical excision is not possible there are several
therapeutic options such as radiotherapy, systemic chemo-
and polychemotherapy, laser ablation, or radiofrequency
ablation [3-5] .Several recent clinical studies proposed
electrochemotherapy (ECT) as a novel, complementary
therapeutic weapon for controlling cutaneous and subcu-
taneous metastases [6,7]. ECT is a non-thermal tumor
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ablation modality, based on electroporation. The principle
of the method is the application of electric currents (elec-
tric pulses) to the cancer cells using externally applied
electrical fields, that increase cell membrane permeability
transiently, and enhance the penetration of drugs into
cancer cells, thus facilitating transportation of the che-
motherapeutics into the cancer cells [8,9].
Bleomycin and cisplatin have proven to be the most sui-
table candidates for the combined use with electroporation
based on their chemical properties and molecular intracel-
lular targets. Association with electroporation induces a
cytotoxicity increase of up to 80-fold for cisplatin and up
to 8000-fold for bleomycin [10].
The required dose of bleomycin is 15.000 IU/m2 with
intravenous administration. The application of the electric
pulses without drugs has minimal or no effect on tumor
growth [11-13].
ECT was originally employed for the treatment of
metastatic head and neck cancer and has been used in
the treatment of cutaneous metastases from tumours
independent of histology [14,15].
Methods
This prospective, observational study took place through-
out March 2010 to October 2011. Twelve consecutive
elderly patients (1 man and 11 women) with a median age
of 76 years, with regional or distant skin or subcutaneous
metastases from breast cancer, with or without visceral dis-
ease, were included in the study. Inclusion criteria were as
follows: the tumors were unsuitable for resection or radio-
therapy; they were unresponsive to, or progressed after,
two or three lines of systemic chemotherapy; the patient
Karnofsky performance status was greater than 70%.
Exclusion criteria were: coagulation disorder( A platelet
count < 50000/ml was required, with a prothrombin time
< 40 s and an activated partial thromboplastin time in the
normal range); active infection; progressive visceral disease
or allergy to bleomycin; severe renal or hepatic insuffi-
ciency; short life expectancy (<3 months).
Patient enrollment was carried out according to the
ESOPE criteria [6].
The anesthesiologic technique was a mild general
anesthesia for all the procedures. Bleomycin administra-
tion was followed (Bleomycin Nippon-Kayaku, Sanofi-
Aventis, vials 15 mg, 15,000 UI/m2) by the application of
brief electric pulses to each tumor nodule within 8 min
after intravenous infusion of the drug. Electric currents
were delivered by means of a 2–3-cm long needle elec-
trode according to lesion size. All treatments were per-
formed using the CliniporatorTM device (IGEA Ltd.,
Modena, Italy). For best results, the drug must be adminis-
tered rapidly and the electroporation must begin within
8 min of the complete administration of the drug and is to
be completed in 25 min.
Results
Twelve patients with 142 nodules were treated in one-
day surgery with ECT. The diameter of cutaneous and
subcutaneous metastases was 0.5-1 cm in 7 patiens,
(58.3%), 1,5-2,5 cm in 3 patients (25%), > 3 cm in
2 patients (16.7%).
The median observation time of treated metastases
was 210 days (range 30–354 days). Response rate was
determined at least 30 days after ECT in each case. The
response rate was evaluated according to the Response
Evaluation Criteria in Solid Tumours (RECIST version
1.0) [16].
We observed Complete Response (CR) in 75.3% (107
metastases), Partial Response (PR) in 17% (24 metas-
tases), no change in 7.7% (11 metastases). No serious
ECT-related adverse events were reported; adverse
events consisted of pain in the treated area one to two
days after treatment (1 patient, 8.3%) and ulceration of
treated area (1 patient, 8.3%). One patients developed
dissociative amnesia and agitation that was treated with
antipsychotic drug (i.m. clorpromazine).
Eight patients received a single ECT session (66.6%).
A second treatment was performed in 4 patients
(33.3%); one of them underwent a third ECT treat-
ment. These four patients underwent a second session
to treat the nodules that remained after the first
course; one patients underwent a third treatment for
both new and previously treated lesions and always
maintained a PR with respect to the initial measure-
ment. A second ECT course to treat new lesions was
performed after a median of 3 (range 2–9) months
after the first treatment.
Discussion
Cutaneous metastases or recurrent malignant disease in
the skin are often difficult to manage. Uncontrolled
cutaneous metastases can, in many ways, adversely affect
self-esteem and body image. Management of metastatic
breast cancer in women over the age of 65 follows the
same principles that guide treatment of younger women,
with few exceptions.
Important issues in older cancer patients such as life
expectancy, comorbidity, and functional status must be
considered when making treatment decisions. Clinical
decision-making, particularly when cytotoxic chemother-
apy is being considered, requires consideration of
whether an individual’s life expectancy is long enough
to obtain benefit from therapy and whether treatment
will be adequately tolerated.
ECT can be used where surgery is not an option and is
also efficient in chemotherapy-resistant and radiotherapy-
resistant lesions [16,17]. Treatment may provide palliation
particularly where there is pain or bleeding from cuta-
neous metastases [18].
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It is well tolerated with few side-effects, allows for
immediate recovery and can be repeated. Several clinical
studies on ECT were published, demonstrating its effi-
cacy in local tumor control of various malignancies. In
ESOPE [6] study 16 patients were treated over 75 years
with significant benefit to them, without side-effects.
Another advantage of ECT is that it is easy and quick to
perform (median time of treatment < 25 min). The trea-
ted tumor nodules are well controlled, and after com-
plete regression of the treated nodules good cosmetic
effect is obtained. ECT is a viable option in the treat-
ment of patients with tumors unsuitable for other thera-
pies, even if only for palliation, improving the quality of
life. ECT is simple, highly effective and safe. The
absence of systemic adverse effects and the low impact
on immune system functions also allow the treatment of
elderly people with repeated courses.
Conclusion
Our results are in agreement with previous studies, sug-
gesting ECT as an effective and safe loco-regional ther-
apy for breast cancer. ECT may be an alternative
treatment modality to conventional therapies, especially
in case of multiple cutaneous and subcutaneous lesions.
It has been proven to relief symptoms of loco-regional
relapse and to improve patients’ quality of life.
Furthermore, ECT also has the potential of being
advocated for the treatment of other clinical conditions,
such as primary local therapy in frail elderly patients
that are not suitable for surgical removal of breast
cancer.
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